Source: Canopy Growth.
  • Canopy Growth (WEED) is announcing the release of Martha Stewart’s pumpkin spice CBD gummies
  • Each limited-edition gummy contains 10 mg of pure CBD isolate
  • The new flavor expands upon Stewart’s partnership with Canopy Growth, where she serves as strategic advisor
  • Canopy Growth is a world-leading diversified cannabis and cannabinoid consumer product company
  • Canopy Growth (WEED) is up by 12.89 per cent trading at $4.73 per share

Canopy Growth (WEED) is announcing the release of Martha Stewart’s pumpkin spice CBD gummies.

The limited-edition gummies – each of which contain 10 mg of pure CBD isolate – are inspired by one of the most recognizable flavors of the fall and designed to complement a wide variety of seasonal activities.

The product will be available this week on Martha Stewart CBD’s official website.

The new flavor expands upon Stewart’s partnership with Canopy Growth, where she serves as strategic advisor.

The Martha Stewart CBD gummies lineup also includes the Tropical Medley CBD Wellness Gummies and Harvest Medley CBD Wellness Gummies.

The Martha Stewart brand is owned by Marquee Brands, a brand accelerator sponsored by Neuberger Berman.

“The pumpkin spice flavor signifies the beginning of the fall season and I wanted to capture this delicious moment with our CBD gummies,” said Martha Stewart. “It’s always important and a pleasure to expand our offerings and continue to make CBD convenient and tasty to enjoy every day.”

Canopy Growth is a world-leading diversified cannabis and cannabinoid consumer product company.

Canopy Growth Stock is up by 12.89 per cent trading at $4.73 per share as of 12:12 pm EST.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.